Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced that they have initiated a long-term Phase 3 of Zerenex (erric citrate).
This article: 91 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE